Drug-drug interactions

Type 2 diabetes mellitus (T2DM) frequently coexists with hypertension, substantially increasing the risk of cardiovascular morbidity, mortality, and progressive renal disease. Contemporary management of these comorbid conditions relies heavily on polypharmacy, with oral antidiabetic drugs and antihypertensive agents prescribed concomitantly for prolonged durations. Among antidiabetic therapies, the fixed-dose combination of glimepiride and metformin remains widely used because it addresses both insulin resistance and impaired insulin secretion. Angiotensin receptor blockers (ARBs) are commonly recommended antihypertensive agents in patients with T2DM due to their established renoprotective and cardioprotective benefits. However, accumulating experimental and clinical evidence suggests that ARBs are not metabolically inert; instead, they may influence glucose homeostasis, insulin sensitivity, and the pharmacokinetic disposition of antidiabetic drugs. These effects raise clinically relevant concerns regarding potential pharmacokinetic and pharmacodynamic interactions when ARBs are co-administered with glimepiride-metformin combinations. Preclinical investigations have demonstrated enhanced hypoglycemic responses when certain ARBs, such as losartan and telmisartan, are combined with glimepiride-metformin, possibly due to synergistic pharmacodynamic actions or alterations in drug metabolism and transport. Telmisartan, in particular, exhibits partial peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist activity, which may confer additional insulin-sensitizing effects. Clinical evidence, however, remains limited and inconsistent, with some studies suggesting modest improvements in glycemic control and others indicating an increased risk of hypoglycemia, especially in regimens containing sulfonylureas. Moreover, most available studies lack integrated pharmacokinetic-pharmacodynamic assessments and fail to reflect chronic real-world combination therapy. This review critically synthesizes current preclinical and clinical evidence on pharmacokinetic and pharmacodynamic interactions between glimepiride-metformin combinations and ARBs. It highlights existing knowledge gaps, underscores the clinical necessity for systematic and ARB specific evaluation, and proposes future research directions aimed at optimizing safety and therapeutic outcomes in patients with coexisting T2DM and hypertension.

Drug-drug interaction is a matter of deep concern as this proves to be the major cause of adverse drug reaction (ADR). It may be on pharmacokinetic or pharmacodynamic level. Pharmacokinetic interactions involve the effect of absorption, distribution, metabolism and excretion whereas pharmacodynamic interactions emphasize mainly on three areas viz.,  interactions that occur at single receptor site, at variety of receptor sites and general non-specific interactions mediated through unspecified sites of action. Different factors are responsible such as genetic constitution, disease, diet, pharmacological response and polypharmacy, age related physiological changes on the basis of the outcomes obtained on the clinical effects of the drug used. This article reflects a clear picture on drug-drug interactions for cytochrome p-450 and non steroidal anti-inflammatory drug (NSAIDs), antihistaminic drugs, antidepressants, interactions with antiretrovirals and Rifampin, anti-anaemic agents, dermatological drugs, antipsychotic drugs, major antibiotics, sedative-hypnotic and anti-cancer drugs.